Back to rankings

Bayer Aktiengesellschaft (BAYRY)

POSITIVE
HealthcareDrug Manufacturers - GeneralGermany

Price

$36.19

Market Cap

$35.55B

Fundamental

65

Technical

85

Composite

71

AI Analysis

Generated on demand using your Gemini API key

Gemini API key not configured

Add your Gemini API key in Settings to unlock AI analysis.

Overview

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Balance Sheet & Liquidity

Revenue

$45.58B

Net Income

$-3.62B

Free Cash Flow

$7.31B

Total Equity

$28.84B

Total Liabilities

$38.89B

Current Ratio

1.05

Interest Coverage

-

Debt/EBITDA

3.83

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Fair Value Estimation

Undervalued

Fair Value

$62.39

Current Price

$36.19

Margin of Safety

+42.0%

Fair Value Range

$40.56 - $84.23

Estimation Methods

Analyst Target:$49.50
DCF:$143.09
PE-based:N/A
Graham Growth:N/A
EPV:$1.05
Analyst Consensus:Buy (21B / 7H / 0S)
Last Earnings Surprise:+5.34%

Valuation Metrics

P/E Ratio

-

ROE

-6.9%

P/B Ratio

1.23

P/FCF

4.86

Gross Margin

59.9%

ROIC

13.9%

Value Creation (Economic Moat)

ROIC

13.9%

WACC

4.6%

ROIC − WACC

+9.3 pp

ROIC exceeds the cost of capital — the company is creating value for shareholders.

Fundamental Analysis Criteria

Passed (11)

  • ROIC 13.9%
  • Gross Margin 59.9%
  • P/FCF 4.86
  • P/B Ratio 1.23
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • DCF valuation (Undervalued)
  • Analyst Consensus 75% Buy
  • Earnings Surprise avg 36.1%

Failed (6)

  • Price CAGR -9.73%
  • CapEx intensity
  • ROE -7.5%
  • Revenue Growth 5Y 1.9%
  • Net Margin Trend -7.9% vs -5.5%
  • Piotroski F-Score 2/9

Unavailable (10)

  • EPS data insufficient
  • Dividend Payout NaN%
  • Operating Margin NaN%
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)
  • Share Dilution (missing shares data)

Price Chart

Technical Indicators

RSI (14)

45.54

SMA 50

$38.14

SMA 200

$35.51

MACD

0.02

Volatility

2.4%

Momentum (12m)

31.2%

RSI 45.5, SMA trend bullish, momentum 31.2%.

Piotroski F-Score

2/9

Serious financial concerns

score
criteria

Earnings Quality

-

Low quality: investigate accounting

Share Dilution

-

Buying back shares. Shareholder friendly

Governance

Executive Team

NameTitleAge
Mr. William N. AndersonChairman of the Management Board & CEO59
Mr. Stefan OelrichHead of the Pharmaceuticals Division & Member of the Board of Management57
Ms. Heike PrinzChief Talent Officer, Labor Director & Member of Management Board61
Dr. Judith HartmannCFO & Member of Management Board56
Mr. Rodrigo SantosMember of Management Board, Head of the Crop Science Division & President of Crop Science Division52
Mr. Julio TrianaMember of Management Board & President of Consumer Health Division60
Mr. Alex BuschermohleChief Information Officer, Head-Digital Transformation & IT-Crop Science Division-
Dr. Jost ReinhardSenior VP & Head of Investor Relations53
Mr. Bill DoderoGeneral Counsel and Senior VP of Law Patents & Compliance-
Mr. Michael PreussHead of Communications, Government Relations and Corporate Brand-

Audit Risk

6

Board Risk

1

Compensation Risk

2

Shareholder Rights Risk

1

Latest News

Recent headlines for BAYRY, sourced from Markets Gazette.

No recent news for BAYRY.
Disclaimer

This platform is for educational purposes only. It does not provide financial, investment, or trading advice. All scores, valuations, and signals are based on automated analysis of publicly available data that may be incomplete or inaccurate. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Created by CODEPRESS s.r.l.